A joint WTO communication released by Mexico and Switzerland earlier this month reveals just how senseless a proposed patent waiver for Covid-19 diagnostics and therapeutics is — and just how far the United States has retreated from global leadership on IP. The letter, addressed to the WTO’s TRIPS Council, comes just weeks before a critical …
On TRIPS waiver extension, America must stand up — not stand by Read More »
President Biden recently set a goal of slashing cancer death rates by at least 50 percent in the next 25 years — and announced billions of dollars in new research funding to make it a reality. It’s a plan with sky-high ambitions, a real “cancer moonshot,” as the president has branded it.
By December 17, the World Trade Organization TRIPS Council is obligated to decide whether to extend the current waiver on Covid-19 vaccines to therapeutics and diagnostics. During recent informal meetings of the Council, South Africa and India remained the most vocal proponents of the expanded waiver. The European Union, the United Kingdom, and the United States have yet to take …
Don’t suspend IP protections on Covid-19 diagnostics and therapeutics Read More »
WASHINGTON (October 26) — This week, the Council for Innovation Promotion, a bipartisan coalition dedicated to promoting strong and effective intellectual property rights, launched its first major advertising campaign to highlight the important role Members of Congress play in ensuring the United States maintains its leadership in the innovation economy. C4IP’s digital advertisements will celebrate …
“Any suggestion that this legislation would allow companies to patent anyone’s DNA is simply false,” C4IP writes, adding that the ‘scaremongering’…ignores the fact that the human genome has already been published many times over and is already available for scientific use.”
In their quest to lower drug prices, some US leaders have identified a convenient scapegoat: patents.
Isolated human genes would be patentable, and the costs of medical diagnostic tests would jump under a recently introduced bill to revamp patent eligibility, panelists at an American Civil Liberties Union virtual briefing said Monday—a stance that former patent officials labeled “scaremongering.”
It’s no secret that the film industry looks different than it did when I worked in Hollywood decades ago. Gone are the days when eager movie-goers’ only option was to pile into theaters to watch the latest hit. Today, many Americans can enjoy watching films from the comfort of their own homes. The way we …
Intellectual property rights are the heroes of America’s innovation story Read More »
Medicare has a herculean task ahead of setting up an infrastructure to take on an entirely new function for the program — regulating how much it pays for certain medications, and penalizing drug makers that hike prices faster than inflation. With new responsibility comes new bureaucracy, new documents obtained by STAT show.
Medicare has a herculean task ahead of setting up an infrastructure to take on an entirely new function for the program — regulating how much it pays for certain medications, and penalizing drug makers that hike prices faster than inflation. With new responsibility comes new bureaucracy, new documents obtained by STAT show.
Medicare has a herculean task ahead of setting up an infrastructure to take on an entirely new function for the program — regulating how much it pays for certain medications, and penalizing drug makers that hike prices faster than inflation. With new responsibility comes new bureaucracy, new documents obtained by STAT show.
